Contraceptive Devices Market By Product Type (Intrauterine Devices, Condoms, Diaphragms & Sponges, Implants, Vaginal Rings); By Gender (Female, Male); By Distribution Channel (Hospitals & Clinics, Retail Pharmacies, Online Platforms); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Contraceptive Devices Market – Longer Protection and Wider Access Are Reshaping Contraceptive Spending

The Global Contraceptive Devices Market was valued at USD 15.4 billion in 2025 and is projected to reach USD 25.25 billion by 2032, growing at a CAGR of 8.7%, according to Strategic Market Research.

 

The FDA oversees a wide range of contraceptive options, including long-acting methods, barrier devices, and digital fertility tools. Approved products include IUDs like Mirena and Liletta, the Nexplanon implant (now usable for up to five years), diaphragms such as Caya, and fertility-tracking apps and devices. Development is also moving toward non-surgical sterilization and products that combine pregnancy prevention with STI protection.

 

IUDs are a major category, including hormonal types (Mirena, Kyleena, Liletta, Skyla) and the copper ParaGard, offering 3–8 years of protection. Nexplanon is the main implant option, providing up to five years of contraception. Barrier methods include condoms, diaphragms, and cervical caps, which block sperm physically. Digital tools like Natural Cycles help users track fertility using apps and temperature data.

 

The pipeline includes new approaches such as FemBloc, a non-surgical sterilization method under FDA review. Other developments focus on multipurpose products like vaginal rings that combine contraception with STI protection, as well as non-hormonal, on-demand options like gels and dissolving inserts for immediate use without systemic hormones.

 

How Is the Large Family-Planning Population Expanding Contraceptive Device Demand?

Global modern contraceptive use reached 871 million people in 2024, compared with 552 million in 1994, while more than 250 million women of reproductive age who wanted to avoid pregnancy were not using modern contraception. These figures include non-device methods, but the gap between contraceptive need and use gives manufacturers room to gain new users as family-planning access expands.

U.S. data show particularly strong use of long-acting devices. CDC data for 2022–2023 indicate that 54.3% of females aged 15–49 were currently using contraception. IUDs represented 8.1% of the reported current method classification and implants 2.5%. Applied to the CDC population base, this corresponds to approximately 6.07 million current IUD users and 1.87 million implant users.

Condoms maintain an additional demand base through infection prevention. WHO estimates 374 million new infections from four major curable STIs among adults aged 15–49 in 2020. UNFPA's physical supply also illustrates the difference in product volumes: its programs supplied 1.091 billion male condoms, 4.74 million female condoms, 10.87 million implants, and 2.37 million IUDs in 2025.

 

How Is the Contraceptive Devices Market Segmented by Product Type?

• Intrauterine Devices: IUDs hold the largest product share at 32%, representing approximately USD 4.93 billion in 2025, and are estimated to grow at an 8.0% CAGR to about USD 7.82 billion by 2032. Multi-year protection and strong use of long-acting reversible contraception support the segment. Bayer's Mirena, Kyleena, and Jaydess portfolio generated €1.366 billion in 2025, up 12.5% on a currency- and portfolio-adjusted basis, demonstrating continued commercial demand for hormonal IUDs.

• Condoms: Condoms account for 26% of the market, valued at approximately USD 4.00 billion in 2025, and are forecast to grow at a 7.4% CAGR to around USD 6.14 billion by 2032. Frequent replacement, broad retail availability, STI prevention, and public-health procurement sustain large unit volumes. Church & Dwight expanded the Trojan franchise with its G.O.A.T. non-latex condom, launched in Q4 2025, showing how material innovation and premium positioning continue to create growth within a mature category.

• Diaphragms & Sponges: Diaphragms and contraceptive sponges represent 10% of the market, or about USD 1.54 billion in 2025, and are estimated to expand at a 5.6% CAGR to approximately USD 2.14 billion by 2032. Their smaller position reflects stronger competition from condoms and long-acting methods, but demand continues among consumers seeking hormone-free, user-controlled, and on-demand contraception. SMR's published segment structure identifies this category as a smaller but continuing part of the non-hormonal contraceptive market.

• Implants: Contraceptive implants hold an 18% market share, valued at approximately USD 2.77 billion in 2025, and are projected to be the fastest-growing product category at an estimated 12.5% CAGR, reaching about USD 5.61 billion by 2032. Organon's Nexplanon received a U.S. label extension to five years in January 2026, increasing the duration available from a single placement. The longer duration can delay replacement purchases—Organon reported a 28% U.S. Nexplanon sales decline in Q1 2026 partly because physicians postponed reinsertions—but it strengthens the product's long-duration value and raises the importance of new patient starts and geographic expansion.

• Vaginal Rings: Vaginal rings account for 14% of the market, equivalent to approximately USD 2.16 billion in 2025, and are estimated to grow at an 8.6% CAGR to about USD 3.54 billion by 2032. The segment sits between daily contraception and long-acting clinician-administered devices, appealing to users who prefer a hormonal method that does not require daily dosing. Wider familiarity with non-daily contraception and continued availability through prescription and pharmacy channels support demand. SMR's product segmentation places vaginal rings as a meaningful mid-sized category alongside IUDs, condoms, implants, and barrier devices.

 

How Does Gender Shape Contraceptive Device Revenue?

• Female: Female contraceptive devices account for approximately 72% of global revenue, representing USD 11.09 billion in 2025, and are estimated to grow at an 8.2% CAGR to about USD 17.82 billion by 2032. The segment dominates because it includes IUDs, implants, vaginal rings, diaphragms, sponges, and female condoms. Demand also benefits from continued innovation in long-acting methods. Medicines360's April 2026 launch of Avibela in South Africa expanded access to a generic levonorgestrel 52-mg IUD, illustrating how new market entry can broaden female contraceptive availability.

• Male: Male contraceptive devices represent the remaining 28%, valued at approximately USD 4.31 billion in 2025, and are estimated to grow at a 9.5% CAGR to around USD 7.43 billion by 2032. Condoms currently account for most commercial male-device demand, with growth supported by repeat purchasing, STI prevention, product premiumization, and increasing attention to shared contraceptive responsibility. The large consumer reach of condom brands gives this segment a much higher purchasing frequency than most female long-acting devices.

 

How Are Distribution Channels Dividing Contraceptive Device Revenue?

• Hospitals & Clinics: Hospitals and clinics lead distribution with a 46% share, representing approximately USD 7.08 billion in 2025, and are estimated to grow at an 8.3% CAGR to about USD 11.43 billion by 2032. Their dominant position reflects the need for trained providers to insert and remove IUDs and contraceptive implants. Growth in LARC adoption therefore translates directly into demand for provider-based distribution. CooperSurgical's Paragard provides an example of this clinician-focused model, with CooperCompanies reporting that higher Paragard sales contributed to its office and surgical business growth in fiscal 2025.

• Retail Pharmacies: Retail pharmacies hold approximately 34% of the market, valued at USD 5.24 billion in 2025, and are estimated to expand at a 6.7% CAGR to around USD 7.74 billion by 2032. Pharmacies remain important for condoms and other contraceptive products that do not require placement procedures. Their scale comes from convenient access, broad geographic reach, established consumer trust, and repeat purchasing rather than high revenue per individual device.

• Online Platforms: Online platforms account for approximately 20% of the market, or USD 3.08 billion in 2025, and are forecast to be the fastest-growing distribution channel at an estimated 12.0% CAGR, reaching about USD 6.08 billion by 2032. Privacy, home delivery, wider product choice, and increasing digital-health engagement are encouraging consumers to purchase condoms and other self-managed contraceptive products online. SMR identifies online platforms as the fastest-growing distribution mode, particularly across North America, Europe, and urban Asia.

 

Which Regions Are Creating the Strongest Contraceptive Device Opportunities?

• North America: North America accounts for approximately 28% of global revenue, representing USD 4.31 billion in 2025, and is forecast to grow at a 7.6% CAGR to about USD 6.69 billion by 2032. High contraceptive awareness, established OB/GYN networks, insurance-supported access, and strong use of IUDs, implants, and branded condoms sustain the region's leading revenue position. Bayer, Organon, CooperSurgical, and Church & Dwight all have significant exposure to the U.S. contraceptive market.

• Europe: Europe represents approximately 27% of the global market, valued at USD 4.16 billion in 2025, and is estimated to grow at a 6.5% CAGR to around USD 6.07 billion by 2032. Mature public healthcare systems and established use of both hormonal and barrier contraception support demand. Bayer's hormonal IUD portfolio and Reckitt's Durex business give the region a combination of clinician-led and consumer-product competition.

• Asia-Pacific: Asia-Pacific accounts for approximately 18% of the market, representing USD 2.77 billion in 2025, and is projected to be the fastest-growing region at a 10.8% CAGR, reaching around USD 5.13 billion by 2032. Growth is tied to broader access to modern contraception, expanding urban healthcare, family-planning programs, and increasing availability through private retail channels. India, China, and other large Asian markets provide substantial opportunities for both high-volume condoms and long-acting methods.

• Latin America: Latin America holds an estimated 15% share, valued at approximately USD 2.31 billion in 2025, and is forecast to expand at a 9.6% CAGR to about USD 4.00 billion by 2032. Brazil and other large urban markets are seeing wider interest in long-acting contraception alongside established condom use. Organon has reported improving Nexplanon demand and access in Brazil, demonstrating how geographic expansion can create new implant users rather than relying entirely on mature-market replacement cycles.

• Middle East & Africa: Middle East & Africa represents an estimated 12% of the market, or approximately USD 1.85 billion in 2025, and is projected to grow at a 10.5% CAGR to about USD 3.36 billion by 2032. Public family-planning programs, international procurement, and wider availability of affordable contraceptives are central to growth. Medicines360 and Pharma Dynamics' launch of Avibela in South Africa in April 2026 demonstrates how lower-cost long-acting products can expand competition and access in underserved markets.

 

Who Is Competing for the Next Contraceptive-Device User?

• Bayer – Hormonal IUD Market Leader
  Bayer's contraceptive portfolio includes Mirena, Kyleena, and Jaydess, giving the company a strong position in hormonal IUDs. Combined sales reached €1.366 billion in 2025, compared with €1.267 billion in 2024.

• Organon – Long-Acting Hormonal Contraception Specialist
  Organon competes through Nexplanon/Implanon NXT and NuvaRing. Nexplanon's five-year U.S. duration strengthens its long-acting positioning, while the resulting delay in reinsertions shows how longer device life can shift revenue toward new patient acquisition and geographic expansion.

• CooperSurgical – Non-Hormonal IUD Provider
  CooperSurgical participates through Paragard, providing a non-hormonal copper-IUD option in the U.S. Higher Paragard sales contributed to CooperCompanies' office and surgical business growth during fiscal 2025.

• Reckitt – Global Condom Brand Leader
  Reckitt competes through Durex, where revenue depends on frequent consumer purchases rather than multi-year replacement cycles. Product differentiation, brand recognition, retail distribution, and e-commerce remain central to its position in condoms.

• Church & Dwight – Premium Condom Innovator
  Church & Dwight's Trojan franchise gives it a strong U.S. condom presence. The company's G.O.A.T. non-latex launch demonstrates continued investment in alternative materials and premium products designed to encourage consumers to trade up within the condom category.

• Medicines360 – Affordable Long-Acting Contraception Expander
  Medicines360 participates through Liletta and Avibela, combining hormonal-IUD development with broader contraceptive access. Its 2026 South African Avibela launch expanded its presence in Africa and added competition in affordable long-acting reversible contraception.

 

Market Outlook 2032

Competition through 2032 will increasingly reflect differences in contraceptive duration, method preference, provider access, repeat-purchase frequency, and geographic reach. IUDs remain the largest product revenue pool, while implants offer the strongest product growth outlook. Female devices retain the majority of spending because of the breadth of available methods, while male devices benefit from large recurring condom volumes. Hospitals and clinics continue to anchor clinician-administered contraception, but online platforms are gaining importance for consumer-controlled products. Regionally, North America remains the largest revenue market, while Asia-Pacific and emerging markets provide stronger expansion opportunities as modern contraceptive access broadens.

 

Contraceptive Devices Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 15.4 Billion
Revenue Forecast in 2032	USD 25.25 Billion
Overall Growth Rate	CAGR of 8.7% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product Type, By Gender, By Distribution Channel, By Geography
By Product Type	Intrauterine Devices, Condoms, Diaphragms & Sponges, Implants, Vaginal Rings
By Gender	Female, Male
By Distribution Channel	Hospitals & Clinics, Retail Pharmacies, Online Platforms
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Longer protection periods offered by long-acting reversible contraceptive devices, expanding access to modern family-planning services, persistent unmet contraceptive need across reproductive-age populations, and recurring condom demand supported by pregnancy and STI prevention
Customization Option	Available upon request